SGMT Stock Up 12.6% on FDA Fast Track for Liver Disease Drug
Sagimet Biosciences’ SGMT stock rose 12.6% on Tuesday after it announced that the FDA has granted breakthrough therapy designation (“BTD”) to its lead pipeline candidate, denifanstat, for treating...
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.